Scotland accepts Roche's Mabthera but rejects its Herceptin for use on NHS
This article was originally published in Scrip
Executive Summary
The Scottish Medicines Consortium (SMC), Scotland's health technology assessment body, has recommended Roche's Mabthera (rituximab) as a maintenance therapy for treating follicular lymphoma after induction therapy. But it has again rejected the firm's Herceptin (trastuzumab) for patients with metastatic stomach cancer.